Available Data
We are building a bioinformatic database of liver and lung cancer data that will be available in December 2019—we are now pre-marketing the data.
Coming December
9,000+
Liver Cancer Matched Biosamples
Liver cancer incidence in Taiwan exceeds 11,000 cases per year with patients receiving some of the most advanced treatment in the world.
3,000+
Lung Cancer Matched Biosamples
Taiwan’s NHIA has recently approved some immunotherapies for reimbursement allowing the accumulation of efficacy data vs. genotype.
Matched Biosamples
Pairs of both healthy and cancerous biosamples.
Precision
From lower cost SNP to WGS/WES datasets, GeneRight™ leverages Taiwan’s world class medical and technical processes and platforms.
Real-World Evidence
Sources matching medical reimbursement and relevant personal medical data.
Scalable
Datasets consistently integrated from multiple biobank sources.
Compliant
Meets the terms of Taiwan's Personal Information Privacy Act and Bio-Bank Act, plus other relevant laws.
Market Demand
The GeneRight™ Taiwan data source covers the breadth of the Han Chinese genome.
Paired Data
Data includes cancer type, age, gender and some clinical history.